84 related articles for article (PubMed ID: 15289350)
1. Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators.
Batra S; Reynolds CP; Maurer BJ
Cancer Res; 2004 Aug; 64(15):5415-24. PubMed ID: 15289350
[TBL] [Abstract][Full Text] [Related]
2. Alkaline ceramidase 2 (ACER2) and its product dihydrosphingosine mediate the cytotoxicity of N-(4-hydroxyphenyl)retinamide in tumor cells.
Mao Z; Sun W; Xu R; Novgorodov S; Szulc ZM; Bielawski J; Obeid LM; Mao C
J Biol Chem; 2010 Sep; 285(38):29078-90. PubMed ID: 20628055
[TBL] [Abstract][Full Text] [Related]
3.
Hayashi Y; Tsuchiya K; Yamamoto M; Nemoto-Sasaki Y; Tanigawa K; Hama K; Ueda Y; Tanikawa T; Gohda J; Maeda K; Inoue JI; Yamashita A
J Virol; 2021 Aug; 95(17):e0080721. PubMed ID: 34106748
[TBL] [Abstract][Full Text] [Related]
4. Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives.
Cooper JP; Reynolds CP; Cho H; Kang MH
Exp Biol Med (Maywood); 2017 Jun; 242(11):1178-1184. PubMed ID: 28429653
[TBL] [Abstract][Full Text] [Related]
5. Fenretinide induces mitochondrial ROS and inhibits the mitochondrial respiratory chain in neuroblastoma.
Cuperus R; Leen R; Tytgat GA; Caron HN; van Kuilenburg AB
Cell Mol Life Sci; 2010 Mar; 67(5):807-16. PubMed ID: 19941060
[TBL] [Abstract][Full Text] [Related]
6. Ceramide-tamoxifen regimen targets bioenergetic elements in acute myelogenous leukemia.
Morad SA; Ryan TE; Neufer PD; Zeczycki TN; Davis TS; MacDougall MR; Fox TE; Tan SF; Feith DJ; Loughran TP; Kester M; Claxton DF; Barth BM; Deering TG; Cabot MC
J Lipid Res; 2016 Jul; 57(7):1231-42. PubMed ID: 27140664
[TBL] [Abstract][Full Text] [Related]
7. Role of reactive oxygen species in the synergistic cytotoxicity of safingol-based combination regimens with conventional chemotherapeutics.
Ling LU; Tan KB; Chiu GN
Oncol Lett; 2011 Sep; 2(5):905-910. PubMed ID: 22866148
[TBL] [Abstract][Full Text] [Related]
8. In vitro activities of novel 4-HPR derivatives on a panel of rhabdoid and other tumor cell lines.
Smith ME; Das BC; Kalpana GV
Cancer Cell Int; 2011 Sep; 11():34. PubMed ID: 21951911
[TBL] [Abstract][Full Text] [Related]
9. Lipid-Restricted Culture Media Reveal Unexpected Cancer Cell Sensitivities.
Goldfarb RB; Atala Pleshinger MJ; Yan DF; Adams DJ
ACS Chem Biol; 2024 Apr; 19(4):896-907. PubMed ID: 38506663
[TBL] [Abstract][Full Text] [Related]
10. Validated LC-MS/MS Assay for the Quantitative Determination of Fenretinide in Plasma and Tumor and Its Application in a Pharmacokinetic Study in Mice of a Novel Oral Nanoformulation of Fenretinide.
Matteo C; Orienti I; Eramo A; Zeuner A; Ferrari M; Passoni A; Bagnati R; Ponzo M; Bello E; Zucchetti M; Frapolli R
Pharmaceutics; 2024 Mar; 16(3):. PubMed ID: 38543281
[TBL] [Abstract][Full Text] [Related]
11. Acid Ceramidase Inhibitor LCL-805 Antagonizes Akt Signaling and Promotes Iron-Dependent Cell Death in Acute Myeloid Leukemia.
Ung J; Tan SF; Fox TE; Shaw JJP; Taori M; Horton BJ; Golla U; Sharma A; Szulc ZM; Wang HG; Chalfant CE; Cabot MC; Claxton DF; Loughran TP; Feith DJ
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136410
[TBL] [Abstract][Full Text] [Related]
12. Acid Ceramidase Inhibitor LCL-805 Antagonizes Akt Signaling and Promotes Iron-Dependent Cell Death in Acute Myeloid Leukemia.
Ung J; Tan SF; Fox TE; Shaw JJ; Taori M; Horton BJ; Golla U; Sharma A; Szulc ZM; Wang HG; Chalfant CE; Cabot MC; Claxton DF; Loughran TP; Feith DJ
bioRxiv; 2023 Oct; ():. PubMed ID: 37961314
[TBL] [Abstract][Full Text] [Related]
13. Antioxidants and Calcium Modulators Preclude in Vitro Hepatitis B Virus-Induced Mitochondrial Damage.
Jabeen K; Javed A; Manzoor S; Shahzad S
Turk J Gastroenterol; 2023 Oct; 34(10):1052-1061. PubMed ID: 37565795
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous Inhibition of Ceramide Hydrolysis and Glycosylation Synergizes to Corrupt Mitochondrial Respiration and Signal Caspase Driven Cell Death in Drug-Resistant Acute Myeloid Leukemia.
Fisher-Wellman KH; Kassai M; Hagen JT; Neufer PD; Kester M; Loughran TP; Chalfant CE; Feith DJ; Tan SF; Fox TE; Ung J; Fabrias G; Abad JL; Sharma A; Golla U; Claxton DF; Shaw JJP; Bhowmick D; Cabot MC
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980769
[TBL] [Abstract][Full Text] [Related]
15. Lethal Phenotype-Based Database Screening Identifies Ceramide as a Negative Regulator of Primitive Streak Formation.
Pu J; Kofuji S; Okamoto-Uchida Y; Danzaki K; Yu R; Suzuki A; Kitajima S; Nishina H
Stem Cells; 2023 Dec; 41(12):1142-1156. PubMed ID: 37819786
[TBL] [Abstract][Full Text] [Related]
16. Fenretinide binding to the lysosomal protein saposin D alters ceramide solubilization and hydrolysis.
Milliken BT; Melegari L; Smith GL; Grohn K; Wolfe AJ; Moody K; Bou-Abdallah F; Doyle RP
RSC Med Chem; 2020 Sep; 11(9):1048-1052. PubMed ID: 33479697
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of intravenous fenretinide (4-HPR) plus safingol in advanced malignancies.
Boulter AC; Maurer BJ; Pogue M; Kang MH; Cho H; Knight A; Reynolds CP; Quick D; Awasthi S; Gerber DE
Cancer Chemother Pharmacol; 2023 Aug; 92(2):97-105. PubMed ID: 37199745
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia and HIFs in Ewing sarcoma: new perspectives on a multi-facetted relationship.
Ceranski AK; Carreño-Gonzalez MJ; Ehlers AC; Colombo MV; Cidre-Aranaz F; Grünewald TGP
Mol Cancer; 2023 Mar; 22(1):49. PubMed ID: 36915100
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors.
Thomas JS; El-Khoueiry AB; Maurer BJ; Groshen S; Pinski JK; Cobos E; Gandara DR; Lenz HJ; Kang MH; Reynolds CP; Newman EM
Cancer Chemother Pharmacol; 2021 Apr; 87(4):525-532. PubMed ID: 33423090
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
